Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paricalcitol versus alfacalcidol for secondary hyperparathyroidism in hemodialysis patients
NL-OMON31628Not yet recruiting
- Sponsor
- OLVG
- Start
- Aug 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of paricalcitol and alfacalcidol in secondary hyperparathyroidism (SHPT) (2 arms), sponsored by OLVG. Primary endpoint: Mean parathyroid hormone level. Planned start Aug 2008; status: not yet recruiting.
02
Drugs
paricalcitolalfacalcidol
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NL-OMON31628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31628.